Brief: Axovant Provides Clinical Program Update For Axo-Aav-Gm1

Sio Gene Therapies

19/12/2019 22:42

Dec 19 (Reuters) - Axovant Gene Therapies Ltd  AXGT.O :
    * AXOVANT PROVIDES CLINICAL PROGRAM UPDATE FOR AXO-AAV-GM1
    * AXOVANT GENE THERAPIES LTD - AXO-AAV-GM1 WAS GENERALLY
WELL
TOLERATED
    * AXOVANT - PRELIMINARY FINDINGS SUGGEST SAFETY,
TOLERABILITY,
CLINICAL IMPROVEMENT IN FIRST CHILD DOSED WITH GENE THERAPY FOR
GM1 GANGLIOSIDOSIS
    * AXOVANT GENE THERAPIES LTD - HOPING TO COMPLETE ENROLLMENT
IN
PART A OF ONGOING REGISTRATIONAL STUDY IN EARLY 2020
    * AXOVANT GENE THERAPIES - NO REPORTS OF SERIOUS ADVERSE
EVENTS
RELATED TO INVESTIGATIONAL GENE THERAPY OR INTRAVENOUS
ADMINISTRATION OF VECTOR IN STUDY

Source text for Eikon:  ID:nGNXh6jtk 
Further company coverage:  AXGT.O 

 ((Reuters.Briefs@thomsonreuters.com;))